Centessa Pharmaceuticals plc ADR’s recent filing unveils that its President, Orexin Program Accardi Mario Alberto unloaded Company’s shares for reported $0.17 million on Sep 16 ’25. In the deal valued at $21.40 per share,8,172 shares were sold. As a result of this transaction, Accardi Mario Alberto now holds 197,394 shares worth roughly $4.5 million.
Then, Accardi Mario Alberto bought 8,172 shares, generating $180,274 in total proceeds.
Before that, HUSSAIN IQBAL J sold 6,000 shares. Centessa Pharmaceuticals plc ADR shares valued at $131,101 were divested by the General Counsel at a price of $21.85 per share. As a result of the transaction, HUSSAIN IQBAL J now holds 105,386 shares, worth roughly $2.4 million.
Wells Fargo initiated its Centessa Pharmaceuticals plc ADR [CNTA] rating to an Overweight in a research note published on September 03, 2025; the price target was $31. Truist began covering CNTA with “Buy” recommendation on July 21, 2025. Needham started covering the stock on May 28, 2025. It rated CNTA as “a Buy”.
Price Performance Review of CNTA
On Friday, Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] saw its stock fall -0.78% to $22.79. Over the last five days, the stock has gained 4.49%. Centessa Pharmaceuticals plc ADR shares have risen nearly 39.99% since the year began. Nevertheless, the stocks have risen 36.06% over the past one year.
How much short interest is there in Centessa Pharmaceuticals plc ADR?
A steep rise in short interest was recorded in Centessa Pharmaceuticals plc ADR stocks on 2025-08-29, growing by 0.91 million shares to a total of 5.27 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 4.36 million shares. There was a rise of 17.2%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 08, 2025 when Chardan Capital Markets began covering the stock and recommended ‘”a Buy”‘ rating along with a $30 price target.
